28A-1090708
Re-folded human serum albumin was shown to be effectively cytotoxic to various types of cancers. Composition of the re-folded human serum albumin and its application in treating subjects having cancer are disclosed. The present disclosure is related to making and using anti-cancer re-folded human serum albumin (rfHSA) as therapeutics and vaccine. The rfHSA is a monomer and has the same primary protein sequence as naïve human serum albumin. However, at least 3 of the 17 intramolecular disulfide bonds of naïve human serum albumin are disrupted in rfHSA to make rfHSA not only distinguishable from naïve human serum albumin but also a novel protein as shown by limited proteolysis followed by liquid chromatography-tandem mass spectrometry analysis.
- Easy to produce
- Long half time
- Require minute amount for therapeutic or preventive vaccine use
- Anti-cancer therapeutics
- Anti-cancer vaccine
- Therapeutics for Akt dysregulated symptoms or diseases
Chi-Ming Liang, Chung-Hsuan Chen, Shu-Mei Liang, Jeng-Jer Shieh
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Anti-tumor Re-folded Human Serum Albumin Methods and Compositions